Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACER Acer Therapeutics	$0.66	$0.74	$0.55 ▼ $4.56	$16.15M	N/A	N/A	574,675 shs
ANRO Alto Neuroscience	$2.47 +1.2%	$2.58	$1.60 ▼ $17.55	$66.87M	2.16	378,962 shs	134,668 shs
BYSI BeyondSpring	$1.74 +12.3%	$1.51	$0.98 ▼ $3.63	$70.15M	0.21	28,986 shs	62,755 shs
SKYE Skye Bioscience	$2.18 +9.0%	$1.53	$1.14 ▼ $13.51	$67.53M	1.88	353,085 shs	302,200 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACER Acer Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
ANRO Alto Neuroscience	+1.23%	+8.33%	+14.09%	-44.68%	-84.07%
BYSI BeyondSpring	+12.26%	+16.00%	+25.54%	-1.42%	-13.43%
SKYE Skye Bioscience	+8.73%	+26.74%	+36.85%	-41.87%	-83.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACER Acer Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ANRO Alto Neuroscience	1.8393 of 5 stars	3.3	2.0	0.0	0.0	1.6	0.0	0.6
BYSI BeyondSpring	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SKYE Skye Bioscience	1.3353 of 5 stars	3.5	1.0	0.0	0.0	2.6	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACER Acer Therapeutics	0.00	N/A	N/A	N/A
ANRO Alto Neuroscience	2.57	Moderate Buy	$15.40	523.48% Upside
BYSI BeyondSpring	0.00	N/A	N/A	N/A
SKYE Skye Bioscience	3.00	Buy	$16.60	661.47% Upside

Current Analyst Ratings Breakdown

Latest ACER, BYSI, ANRO, and SKYE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/7/2025	ANRO Alto Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00
3/21/2025	ANRO Alto Neuroscience	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
3/21/2025	SKYE Skye Bioscience	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $14.00
3/21/2025	SKYE Skye Bioscience	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
2/28/2025	SKYE Skye Bioscience	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform

(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACER Acer Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	N/A	N/A
BYSI BeyondSpring	$1.88M	37.39	N/A	N/A	($0.91) per share	-1.91
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	($0.17) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACER Acer Therapeutics	-$26.24M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ANRO Alto Neuroscience	-$36.31M	-$2.54	N/A	N/A	N/A	N/A	-49.28%	-33.52%	5/13/2025 (Estimated)
BYSI BeyondSpring	-$21.03M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
SKYE Skye Bioscience	-$37.65M	-$0.72	N/A	N/A	N/A	N/A	-45.78%	-37.44%	N/A

Latest ACER, BYSI, ANRO, and SKYE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	ANRO Alto Neuroscience	-$0.59	N/A	N/A	N/A	N/A	N/A
3/20/2025	Q4 2024	ANRO Alto Neuroscience	-$0.65	-$0.56	+$0.09	-$0.56	N/A	N/A
3/20/2025	Q4 2024	SKYE Skye Bioscience	-$0.30	-$0.24	+$0.06	-$0.24	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACER Acer Therapeutics	N/A	N/A	N/A	N/A	N/A
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	N/A
BYSI BeyondSpring	N/A	N/A	N/A	N/A	N/A
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACER Acer Therapeutics	N/A	N/A	N/A
ANRO Alto Neuroscience	0.05	13.10	13.09
BYSI BeyondSpring	N/A	1.82	N/A
SKYE Skye Bioscience	N/A	14.19	14.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACER Acer Therapeutics	N/A
ANRO Alto Neuroscience	N/A
BYSI BeyondSpring	40.29%
SKYE Skye Bioscience	21.09%

Insider Ownership

Company	Insider Ownership
ACER Acer Therapeutics	20.20%
ANRO Alto Neuroscience	N/A
BYSI BeyondSpring	29.31%
SKYE Skye Bioscience	3.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACER Acer Therapeutics	30	24.46 million	19.52 million	Not Optionable
ANRO Alto Neuroscience	N/A	27.07 million	N/A	N/A
BYSI BeyondSpring	80	40.32 million	27.59 million	Optionable
SKYE Skye Bioscience	11	30.98 million	29.43 million	Optionable

ACER, BYSI, ANRO, and SKYE Headlines

Recent News About These Companies

Skye Bioscience to Participate in May Investment and Medical Conferences

April 29 at 7:00 AM | globenewswire.com

Skye Bioscience announces inducement grant under Nasdaq listing rule

April 28 at 4:21 AM | markets.businessinsider.com

Skye Bioscience Inc.

April 26, 2025 | barrons.com

Skye Bioscience Grants Stock Options to New Employee Under 2024 Inducement Equity Incentive Plan

April 25, 2025 | quiverquant.com

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

April 25, 2025 | globenewswire.com

Rx Rundown: Merck, the CDC, GSK and more

April 18, 2025 | mmm-online.com

William Blair Predicts Skye Bioscience Q2 Earnings

April 18, 2025 | marketbeat.com

A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value

April 16, 2025 | seekingalpha.com

Skye Bioscience announces new preclinical data for nimacimab

April 15, 2025 | markets.businessinsider.com

Skye Bioscience Stock Rises on Preclinical Data for Weight Loss Drug

April 15, 2025 | marketwatch.com

Skye Bioscience's Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly's Blockbuster Drug In Animal Models

April 15, 2025 | benzinga.com

Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model

April 15, 2025 | globenewswire.com

Skye Bioscience to Conduct Meetings at Piper Sandler Conference

April 14, 2025 | globenewswire.com

Why Skye Bioscience, Inc.’s (SKYE) Stock Is Down 12.88%

April 1, 2025 | aaii.com

Skye Bioscience promotes Tu Diep to COO post

March 25, 2025 | thepharmaletter.com

Earnings call transcript: Skye Bioscience Q4 2024 highlights financials, product progress

March 22, 2025 | uk.investing.com

Skye Bioscience, Inc. (PNK:SKYE) Q4 2024 Earnings Call Transcript

March 22, 2025 | insidermonkey.com

Skye Bioscience, Inc.: Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

March 22, 2025 | finanznachrichten.de

Skye Bioscience price target lowered to $14 from $18 at Craig-Hallum

March 22, 2025 | markets.businessinsider.com

Skye Bioscience’s Positive Earnings Call Highlights Nimacimab Progress

March 21, 2025 | tipranks.com

Skye Bioscience reports Q4 EPS (24c), consensus (24c)

March 21, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACER, BYSI, ANRO, and SKYE Company Descriptions

Acer Therapeutics NASDAQ:ACER

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. The company's pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-801 for the treatment of induced Vasomotor Symptoms, post-traumatic stress disorder, and prostate cancer; and OLPRUVA, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease. It has a license agreement with Sanofi to acquire worldwide rights to Osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist; an option agreement with Relief for the development, regulatory approval, and commercialization of OLPRUVA; and an agreement with Emory University to acquire the worldwide intellectual property rights to a family of patents and patent applications related to the use of neurokinin receptor antagonists in managing conditioned fear and treating anxiety disorders, including post-traumatic stress disorder. The company was incorporated in 1991 and is headquartered in Newton, Massachusetts.

Alto Neuroscience NYSE:ANRO

$2.47 +0.03 (+1.23%)

As of 04/30/2025 03:58 PM Eastern

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

BeyondSpring NASDAQ:BYSI

$1.74 +0.19 (+12.26%)

As of 04/30/2025 03:59 PM Eastern

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

Skye Bioscience NASDAQ:SKYE

$2.18 +0.18 (+9.00%)

As of 04/30/2025 04:00 PM Eastern

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time